<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="58"><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication></Indication><Trial id="182510"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>12</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1257">Schizoaffective disorder</Indication><Trial id="226397"></Trial><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="299">Schizophrenia</Indication><Trial id="226397"></Trial><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Trial Of Two Fixed-Doses of ZX-008 (Fenfluramine Hydrochloride) As An Adjunctive Therapy In Children And Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="265344"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Trial Of Two Fixed-Doses of ZX-008 (Fenfluramine Hydrochloride) As An Adjunctive Therapy In Children And Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="265344"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>130</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study on the Usability of the Needle-Free Intraject System in Adult Patients During Acute Migraine Attack</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="210">Migraine</Indication><Trial id="14101"></Trial><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>52</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>ZX-008 Expanded Access Protocol</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="364159"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients></Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Subjects With Osteoarthritis Pain</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><Trial id="208687"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Subjects With Osteoarthritis Pain</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="245">Osteoarthritis</Indication><Trial id="208687"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Trial of Two Fixed Doses of ZX-008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="253849"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>119</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Trial of Two Fixed Doses of ZX-008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="253849"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>119</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="320689"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="717">Seizure disorder</Indication><Trial id="320689"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="320689"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><ProtocolTitle>A Study to Investigate the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="717">Seizure disorder</Indication><Trial id="320689"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>225</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="119">Epilepsy</Indication><Trial id="250920"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="2992">Tonic clonic epilepsy</Indication><Trial id="250920"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="250920"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="3134">Tonic seizure</Indication><Trial id="250920"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>Y</OriginatorSponsored><Patients>13</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><Trial id="206204"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>241</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children &gt;/= 2 Years Old and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="274612"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>87</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children &gt;/= 2 Years Old and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="274612"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>87</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="314867"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="314867"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>20</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, European trial of ZX-008 in dravet syndrome children</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="248686"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>105</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I, open-label, randomized, single-dose, 3-period crossover study to evaluate the pharmacokinetics (PK) and safety of fenfluramine with or without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA) and clobazam(CLB; STP regimen) in healthy adults</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="367677"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A phase I, open-label, randomized, single-dose, 3-period crossover study to evaluate the pharmacokinetics (PK) and safety of fenfluramine with or without a combined antiepileptic drug (AED) regimen of stiripentol (STP), valproate (VPA) and clobazam(CLB; STP regimen) in healthy adults</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="367677"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>26</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="210">Migraine</Indication><Trial id="18493"></Trial><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Treatment of Sunflower Syndrome With ZX-008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4 to 25)</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="119">Epilepsy</Indication><Trial id="365079"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Efficacy</Endpoint><ProtocolTitle>Treatment of Sunflower Syndrome With ZX-008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4 to 25)</ProtocolTitle><TrialStatus>Not yet recruiting</TrialStatus><Indication id="2992">Tonic clonic epilepsy</Indication><Trial id="365079"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>10</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="210">Migraine</Indication><Trial id="76404"></Trial><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>212</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="299">Schizophrenia</Indication><Trial id="87204"></Trial><Drug id="72458">risperidone (sustained release transdermal jet DosePro/SABER, schizophrenia/bipolar disorder), DURECT</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Long-term Prospective study of Fenfluramine in the Patients with Dravet Syndrome</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="162111"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="NS">Phase not specified</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>15</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1257">Schizoaffective disorder</Indication><Trial id="226397"></Trial><Drug id="4236">risperidone</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="299">Schizophrenia</Indication><Trial id="226397"></Trial><Drug id="4236">risperidone</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1257">Schizoaffective disorder</Indication><Trial id="226397"></Trial><Drug id="26832">risperidone (depot injection, Medisorb), J&amp;J</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>Safety and PK Trial With Injectable ZX-003 (Risperidone-SABER) Compared to Risperdal Consta in Stable Schizophrenia</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="299">Schizophrenia</Indication><Trial id="226397"></Trial><Drug id="26832">risperidone (depot injection, Medisorb), J&amp;J</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>60</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="210">Migraine</Indication><Trial id="18493"></Trial><Drug id="4491">sumatriptan</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>54</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="1529">Liver failure</Indication><Trial id="211036"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><Trial id="211036"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication></Indication><Trial id="184571"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>30</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="20">Pain</Indication><Trial id="211235"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><ProtocolTitle>Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment</ProtocolTitle><TrialStatus>Completed</TrialStatus><Indication id="69">Renal failure</Indication><Trial id="211235"></Trial><Drug id="59692">hydrocodone (oral abuse-resistant (BEADTEK), controlled-release (SODAS)), Pernix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>37</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="333045"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="333045"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="333045"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>A Study to Assess the Safety and Tolerability of ZX-008 in Children and Young Adults With DS or LGS Currently Taking CBD</ProtocolTitle><TrialStatus>No longer recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="333045"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>25</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="119">Epilepsy</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="556">Brain disease</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="119">Epilepsy</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="3132">Lennox Gastaut syndrome</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="556">Brain disease</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy</Endpoint><ProtocolTitle>A Study to Investigate the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="379396"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>650</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Open-Label, Extension Trial to Assess the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="264975"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>232</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><ProtocolTitle>An Open-Label, Extension Trial to Assess the Long-Term Safety of ZX-008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome</ProtocolTitle><TrialStatus>Recruiting</TrialStatus><Indication id="5614">Dravet syndrome</Indication><Trial id="264975"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>232</Patients></Row><Row><Ancestry></Ancestry><Endpoint>Safety,Pharmacokinetics</Endpoint><ProtocolTitle>An open-label, cross-over, phase I pharmacokinetic and safety profile study to determine the effect of food on the pharmacokinetic properties of fenfluramine</ProtocolTitle><TrialStatus>Status not specified</TrialStatus><Indication id="717">Seizure disorder</Indication><Trial id="358598"></Trial><Drug id="88501">fenfluramine hydrochloride (low-dose oral, Dravet syndrome/Lennox Gastaut), Zogenix</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><OriginatorSponsored>N</OriginatorSponsored><Patients>13</Patients></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>